The discovery of the p73 and p63 genes, homologous to p53 tumor suppressor has uncovered a family of transcription factors and widened the scenario of cell cycle control and apoptosis. We have identified a putative p53-responsive element in the human adenosine deaminase (ADA) gene, an important enzyme involved in nucleotide metabolism, the deficit of which causes the inhibition of DNA synthesis and repair. Here, we demonstrate that the ectopic expression of p73 isoforms leads to the ADA gene upregulation, showing for the first time a correlation between p73 and ADA. We found that p73 promotes ADA gene expression following a dNTP unbalance generated by ADA enzyme deficiency and 2 0 deoxyadenosine accumulation. The abrogation of p73 transcriptional activity by the specific dominant-negative p73DD abolishes ADA induction. By contrast, the ADA gene does not appear to be a functional p53 target in the physiological conditions we tested. On the whole, our results contribute to the emerging picture that p73 could play a different role from p53 in normal growth and development by inducing alternative target genes, which are not shared by p53.
Introduction
The p73 protein has been identified as a member of the p53 tumor suppressor gene family, which also includes the p63 protein (Kaghad et al., 1997; Yang et al., 1998) . Although the three proteins share similar structural and functional properties and operate as transcription factors, each of them appears to play a distinct role in the development and tumor suppression (D'Erchia et al., 2003) . p53 is a vital player in the complex pathway governing the cell cycle and for this reason it has been recognized as a master switch for growth control with a clear role in tumor suppression (Ko and Prives, 1996;  Hansen and Oren, 1997; Levine, 1997; Vogelstein et al., 2000) . The contribution of p73 and p63 to tumor development is much less well established and, in contrast to p53, p63 and p73 are rarely mutated in human cancers (Yang et al., 2002) . p73 and p63 have an additional domain in their C-terminus with marked similarity with the structure of sterile alpha motif (SAM) domains, typical of proteins involved in development. p73-deficient mice have neurological, pheromonal and inflammatory defects, while p63 is required for limb and epidermal morphogenesis (Mills et al., 1999; Yang et al., 1999 . Different from p53, both p73 and p63 produce many isoforms, resulting from alternative splicing and from initiation of transcription at different promoters (Levrero et al., 2000; Yang and McKeon, 2000) . p53 and p73 are both induced by DNA damage, although through distinct mechanisms, and p73 can bind to the p53-responsive elements (REs), which consist of at least a double decamers (5 0 -PuPuPuC(A/ T)(T/A)GPyPyPy-3 0 ) (El Deiry et al., 1992; Bourdon et al., 1997) and can activate some p53-regulated genes, suppress growth or induce apoptosis. The mechanisms through which p53 and p73 activate transcription seem to be similar, also because their activation domains require the activity of the p300/CBP protein (Lohrum and Vousden, 2000; Zeng et al., 2000) . However, differential activation of genes by p53 and p73 has also been reported (Di Como et al., 1999; Steegenga et al., 1999) .
Of special importance in order to understand the pleiotropic character of p53 and its functional relationship with the other family members is the identification of the genes transactivated by them. Until now, many candidate genes have been proposed for p53 transactivation (Yu et al., 1999) , but little is known about target genes specifically activated by p63 and/or by p73 (Ueda et al., 2001 ; Zheng and Chen, 2001; Balint et al., 2002; Fontemaggi et al., 2002; Sasaki et al., 2002) . It also remains to be determined whether and how different stimuli selectively recruit one or more members of the p53 family to achieve specialized transcription responses in specific cellular contexts.
In the present work, we have identified an RE for p53 family members in the human adenosine deaminase (ADA) gene, a key enzyme in the nucleotide pathway. ADA catalyses the deamination of adenosine and deoxyadenosine to inosine and deoxyinosine, respectively. ADA has been found in a wide variety of microorganisms, plants and invertebrates and is present in all mammalian tissues. The primary mechanism for the control of this ubiquitous enzyme is at the level of transcription. ADA gene is expressed in all cells, although both the level of expression and the induction by different stressors have a high variability among different cell types. The high concentration of ADA mRNA in T cells is controlled by a T-cell-specific enhancer in the first intron of the gene (Aronow et al., 1992) . The promoter region lacks the 'TATA' and 'CAAT' sequences, is extremely G/C rich and possesses multiple functional Sp1 binding sites that are necessary for both basal and T-cell enhancer-driven activation of this promoter (Dusing and Wiginton, 1994) . The essential role played by this enzyme was first indicated in lymphocytes by the finding of an inherited severe combined immunodeficiency disease (SCID) associated with congenital absence of ADA (Giblett et al., 1972) . A deficit of ADA enzyme causes cellular stress due to the unbalance of dNTPs leading to the inhibition of DNA replication and repair.
The experiments described here show that the ADA gene is a p73 and not a p53 target under different physiological conditions we tested. Our results demonstrate that p73 modulates ADA expression in response to the enzyme deficit through a feedback regulation mechanism.
Our studies show for the first time the correlation between p73 and ADA, an important enzyme involved in nucleotide metabolism.
Results
Transcriptional activation of p53-RE in the ADA gene by transient cotransfection with p53, p73a and p73b
In the present work, we have identified a putative p53-RE in the intron 1 of the human ADA gene (ADA-RE) (Figure 1 ). To determine whether p53 family members can transactivate gene expression via this element, we performed a CAT assay. The ADA-RE contains four decamers, each spaced by maximum 10 nucleotides, two decamers are adjacent but for one base and show no mismatch. All decamers have fixed nucleotides at the fourth and the seventh position (C4 and G7) and each double decamer contains a maximum of three mismatches (Figure 1) . A fragment of 367 bp containing the ADA-RE was cloned in the CAT vector pBLCAT2. We also replaced in the ADA sequences eight nucleotides predicted to be critical for p53 binding, which are the C4 and the G7 in each decamer. The resulting recombinant vector was designated mut-ADA-RE (Figure 1 ).
Human p53-null H1299 cells (non-small-cell lung carcinoma) were transiently cotransfected with the recombinant CAT plasmids, pBLCAT2-ADA-RE or pBLCAT2-mut-ADA-RE, with either a pcDNA3 control vector or a vector containing wild-type (wt) p53 (pcDNA 3 p53wt) or the H175 mutant version (pcDNA 3 H175p53). As shown in Figure 2a , CAT experiments demonstrated that ADA-RE shows an enhancer activity for p53 (about 50-fold higher CAT expression compared to the control). The activation was dependent on functional p53 since the transactivation defective mutant p53H175 was incapable of activating the reporter construct. Moreover, mut-ADA-RE, which carries mutations at the fourth and seventh positions in each decamer of ADA-RE (Figure 1 ) was weakly responsive to wt p53 activation. These results indicate that ADA-RE can support the p53-mediated transcriptional activation. Since it has been reported that the ectopic expression of p73 isoforms transactivates many p53-responsive promoters with relative Figure 1 Schematic map of the 5 0 genomic region of the human ADA gene, containing the putative p53-RE (ADA-RE). White boxes represent exons. The T-cell enhancer is indicated with a black box. ADA-RE is located in intron 1 (13813-14180). The decamers are boxed and the nucleotides mismatched from the consensus sequences for p53 binding are in lower case. Mutations introduced into mut-ADA-RE at the C and G at the fourth and the seventh position in each decamer are indicated with arrowheads efficiency differences, we wanted to verify whether ADA-RE is also a p73 target. To this end, p53-null H1299 cells were transiently cotransfected with the recombinant CAT plasmids pBLCAT2-ADA-RE or pBLCAT2-mut-ADA-RE alone or together with an expression vector containing either p73a or p73b splice variants (pcDNA 3 p73a, pcDNA 3 p73b). Interestingly, ADA-RE shows a more powerful enhancer activity for p73, in particular for p73b splice variant since cells cotransfected with pBLCAT2-ADA-RE and p73a or p73b show 60-and 450-fold higher CAT expression, respectively, compared to cells transfected with pBLCAT2-ADA-RE alone (Figure 2b ). The activation was dependent on functional p73 since a mutant p73 that is not able to bind DNA (p73A156 V) was incapable of inducing transcription from the same reporter construct. Moreover, mut-ADA-RE was weakly responsive to wt p73a and p73b activation. To rule out the possibility that the greater transcriptional activity of p73b is due to a higher level of protein expressed, we measured the level of exogenously expressed p53 and p73 in H1299 by Western blot analysis (Figure 2a and b, lower panels). As shown in Figure 2a , b even if p53 level is higher than that of p73a and p73b, it is less active than p73b in activating ADA-RE.
As a control of the specificity of the activities of p53 and p73, we used the pG13CAT reporter vector, which contains 13 copies of the p53 binding site (Figure 2c ). The activation of the pG13CAT reporter was mediated in the most efficient way by p53, whereas the p73 isoforms activated ADA-RE better than p53 (Figure 2a-c) .
These experiments demonstrate that the putative p53-RE located in intron 1 of the ADA gene has an enhancer activity both for p53 and p73, although with an extremely different efficiency (50-fold higher CAT expression for p53 compared to 450-fold for p73b).
ADA is not a p53 target gene in different physiological conditions
Since the presence of a p53 target sequence in a gene does not in itself imply its regulation by p53 and/or p73 (Bian et al., 1996; Werner et al., 1996; Duriez et al., 2000; Sciacchitano et al., 2002) , we verified experimentally, in different physiological conditions, whether or not endogenous expression of the ADA gene is dependent on p53 and/or p73.
We first tested the effect of p53 ectopic expression on the intracellular ADA gene transcription by p53 transfection in the p53-null osteosarcoma SAOS-2 cell line and using the p53-null lung cancer H1299 cell line, Figure 2 Effect of p53 and p73a and p73b on transcriptional activity of ADA-RE. (a) Cotransfection of pcDNA 3 -p53wt (wt p53) or transactivation-defective mutant pcDNA 3 -H175p53 (H175p53) and CAT-reporter gene plasmid pBLCAT2 containing ADA-RE or mut-ADA-RE. (b) Cotransfection of pcDNA 3 -p73a or pcDNA 3 -p73b or transactivation-defective mutant pcDNA 3 -p73-V156A and CAT-reporter gene plasmid pBLCAT2 containing ADA-RE or mut-ADA-RE. (c) Cotransfection of pcDNA 3 -p53wt or pcDNA 3 -H175p53 (H175p53) or pcDNA 3 -p73a or pcDNA 3 -p73b or pcDNA 3 -p73-V156A and CAT-reporter gene plasmids pG13Cat, containing 13 copies of the p53 binding site. CAT expression was quantified by CAT-ELISA and normalized to b-galactosidase activity. The data represent the average of at least three independent experiments and are shown with the standard error Adenosine deaminase gene is a new p73 target A Tullo et al stably transfected with wt p53 under the control of a tetracycline-regulated promoter (H1299-p53-tet). Total RNA was prepared 24 h after p53 transfection in SAOS-2 cells and at different times (8, 12, 18 and 24 h) after p53 induction in H1299-p53-tet and analysed by Northern blot experiments. We found that the ectopic expression of p53 does not induce endogenous ADA mRNA expression in both cell lines ( Figure 3a) . As a control of p53 activation, the same Northern blots were hybridized with one of the principal p53 target genes, p21/Waf1 (cyclin-dependent kinase inhibitor) probe, whereas levels of glyceraldehyde 3-phosphate dehydrogenase (G3PDH) were determined as an equal loading control. The p53 levels in SAOS-2 and in H1299-p53-tet cell lines before and after p53 overexpression were tested by immunoblotting of cell extracts using a polyclonal CM1 antibody against wt p53 ( Figure 3b ). Then we studied whether the endogenous expression of the ADA gene is modulated by p53 under more physiological conditions such as in response to DNA damage. For this purpose ADA mRNA was analysed in the breast cancer cell line MCF-7 and in the human ovarian cancer cell line A2780 (both expressing wt p53) subject to DNA damage known to activate endogenous p53 function. MCF-7 and A2780 cells were exposed to 10 J/m 2 UV light, which does not induce the accumulation of the p73 protein in several cell types (Levrero et al., 2000) . ADA mRNA was analysed 12 h after UV irradiation by Northern blotting (Figure 4a ). Densitometric comparison between ADA mRNA and the housekeeping gene G3PDH showed that in both cell lines, there is no induction of ADA gene expression 12 h after UV irradiation ( Figure 4a ). Any increase in ADA gene expression was also detected at different times after UV irradiation (data not shown). p53 and p21/Waf1 levels were tested at the same time post irradiation by immunoblotting of cell extracts ( Figure 4b ). As expected, p53 and p21 protein levels increased after UV irradiation both in MCF-7 and in A2780 cells.
The above experiments demonstrate that although the ADA gene contains a canonical p53 binding site, which shows an enhancer activity for p53 in CAT assays, ADA does not appear to be a functional p53 target gene in the physiological condition we tested.
ADA gene expression is regulated by p73
Since the CAT experiments reported above demonstrate that the ADA gene seems to be much more efficiently transactivated by p73 than by p53, we evaluated whether the ADA gene could be regulated by p73. At first, we investigated the consequences of p73a overexpression on endogenous ADA gene expression using clones established after the transfection of p73a in the human ovarian cancer cell line A2780. The A2780/ p73a.4 clone showed a level of p73a protein about 10 times higher than the empty vector-transfected cells (A2780/pcDNA 3 ), while the level of p53 does not change in any of the clones (Figure 5a ). The overexpression of p73a did not affect the growth rate of A2780 cells (Vikhanskaya et al., 2000 (Vikhanskaya et al., , 2001 . Total RNA was Figure 5b shows that ADA mRNA was induced in A2780/p73a.4 compared to the control. The same Northern blot was hybridized with the GADD45 probe as a control. In order to test the effect of the ectopic expression of p73b isoform on the intracellular ADA gene transcription, p53-null SAOS-2 cells were transfected with the empty expression vector pcDNA 3 (control) or with the vector containing the a or b p73 splice variants. Densitometric comparison of the Northern blot experiments of ADA mRNA in the control cells and in SAOS-2 cells transfected with p73a or p73b demonstrates that the ectopic expression of the two p73 isoforms analysed, similarly induces endogenous ADA mRNA expression (Figure 5c) , although CAT assays demonstrate that ADA-RE is regulated with high efficiency by the p73b isoform. The p21/Waf1 probe was used in the same analysis as a control of p73 activation. The levels of p73a and p73b isoforms were controlled in SAOS-2 cells after transfection (Figure 5d ). The different levels of ADA mRNA induction after p73 overexpression in A2780 and in SAOS-2 cells could be related to the different protein levels and/or to the different cell lines, since the ADA mRNA expression is extremely variable among different cellular types (Chinsky et al., 1989; Dusing et al., 1997) .
These experiments demonstrate that the ectopic expression of p73 induces ADA gene expression. To determine whether p73 can directly bind to the ADA-RE in vivo, we performed the ChIP assay. Crosslinked chromatin from A2780 cells transfected with p73a or p73b were immunoprecipitated with p73 antibody or with any antibody as a negative control. As shown in Figure 6 , DNA recovered from anti-p73 immunoprecipitation of both A2780p73a and A2780p73b cells was amplified with primers specific for ADA-RE, but not with primers specific for the interleukin-10 promoter, which do not contain any p53/ p73 consensus site, thus indicating that both p73a and p73b bind ADA-RE in vivo in A2780.
To test a physiological condition in which ADA gene expression might be regulated by p73, we tested whether a dNTP unbalance generated by ADA enzyme deficit could activate p73, which consequently would transactivate the ADA gene by a feedback regulation In vivo recruitment of p73a and p73b to ADA-RE. Crosslinked chromatin was extracted from A2780 after transfection of p73a (A2780 p73a) and p73b (A2780 p73b) and immunoprecipitated with anti-p73. The immunoprecipitated material was amplified using primers specific for ADA-RE or for unrelated interleukin-10 promoter (p73DD), which specifically inhibits the activity of p73 proteins. After transfection, to induce endogenous p73 activation, the cells were incubated for 14 h in the absence or in the presence of the indicated amount of dCF and dAdo. The cells were lysed and CAT expression was determined using CAT ELISA (Roche). Transfection efficacy was determined by b-galactosidase activity (b-gal assay, Roche). The data represent the average of at least three independent experiments and are shown with the standard error Adenosine deaminase gene is a new p73 target A Tullo et al mechanism. It has been reported that ADA enzyme deficit causes thymocyte apoptosis mediated by p53 during intrathymic T-cell development (Benveniste and Cohen, 1995) . Nothing is reported in this respect for
p73. Thus, we tested whether ADA deficit could induce cell cycle arrest in G1, instead of apoptosis and whether under these conditions p73 could activate ADA gene expression to make up for the deficit.
Adenosine deaminase gene is a new p73 target A Tullo et al
A number of ADA inhibitors have been designed and usually used to mimic ADA enzyme deficiency (Cristalli et al., 2001) . To induce an ADA deficit, we used 2 0 deoxycoformycin (dCF), a potent ADA inhibitor plus ADA substrate 2 0 deoxyadenosine (dAdo). We found that when used alone, neither dCF nor dAdo causes cellular stress, while their combination determines the inhibition of cell growth (data not shown), as reported in the literature for different cell lines (Benveniste and Cohen, 1995; Camici et al., 1995; Bemi et al., 1998) . The extent of inhibition increased with the increasing time of incubation and concentration of the ADA inhibitor and substrate. The effective concentration of dCF and dAdo and the optimal time of treatment were determined in order to induce cell cycle arrest and not apoptosis (data not shown). dCF was added to the cells 30 min before dAdo.
p53-null H1299 cells, which express a wt p73, were incubated for 14 h in the absence (control) and in the presence of 1 mm dCF and two different dAdo concentrations, 60 and 120 mm. When higher concentrations of dCF and dAdo were used, the cells underwent apoptosis (data not shown). Flow-cytometric analysis was performed to measure the DNA content of the H1299 cells treated with 1 mm dCF and 120 mm dAdo for 14 h. As shown in Figure 7a , the cells were arrested in the G1 and S phase of the cell cycle after treatment with dCF and dAdo. TdT-mediated dUTP nick end labeling (TUNEL) experiments were performed and demonstrate that H1299 cells, treated with 1 mm dCF plus 60 or 120 mm dAdo for 14 h, display a very low level of apoptotic cells (Figure 7b ).
The status of p73 was examined by immunoblotting of cell extracts using the monoclonal antibody p73 against human wt p73. We show for the first time that dCF plus dAdo produce a p73 activation in the H1299 cell line (Figure 7c , compare lanes 2 and 3 with lane 1). We then analysed the ADA mRNA expression by Northern blot experiments in the H1299 cell line treated with the same concentration of dCF plus dAdo. As shown in Figure 7d , ADA expression was induced in p53-null H1299 cell line after ADA enzyme deficit and dAdo accumulation (compare lanes 2 and 3 with lane 1). We observed only a slight increase in p21 level after dCF treatment, but we found a more evident increase in the cyclin-dependent kinase inhibitor p57Kip2, which was recently found to be modulated by p73b and not by p53 (Balint et al., 2002) . The increases of p73 and ADA mRNA levels were found to vary somewhat with cell culture conditions, which are likely to reflect the complex regulation of the ADA gene (Bemi et al., 1998) . To demonstrate that the increasing level of p73 is the cause of the increase in ADA mRNA expression, we transfected H1299 cells with the recombinant reporter plasmid pBLCAT2 containing ADA-RE. As a control of the specificity of the p73 activity, we transfected the recombinant reporter vector pBLCAT3 containing the p21 promoter. After transfection, we induced endogenous p73 activation incubating the cells for 14 h in the absence (control) and in the presence of dCF plus dAdo.
As shown in Figure 7e , there is an increase in CAT expression after the dCF and dAdo treatment. Interestingly, the cotransfection of a dominant-negative form of p73 (p73DD), previously shown to inhibit specifically the activity of p73 proteins completely abolished the CAT expression after dCF treatment, suggesting that endogenous p73 activity is required for proper activation of ADA gene target after dCF treatment.
The experiments reported show that ADA enzyme deficit and dAdo accumulation induces p73 activation, which in turn is required to transactivate ADA gene expression by a feedback regulation mechanism.
Discussion
Extensive research is ongoing to translate the basic knowledge of p53 into the characterization of the other members of the p53 gene family. This occurs in terms of the study of protein structures and functions, such as that of the oncosuppressor and transcription factor. The emerging picture is that p53, p63 and p73 are not interchangeable functionally and are part of a gradient of functions ranging from tumor suppression to development. An unresolved issue regards the ability of the different members of the p53 family to activate specific sets of target genes. The identification of the genes transactivated by the p53 family members is crucial to understand whether each gene has a specific role in cell cycle regulation. At present, little is known about the genes that are preferential targets of p73 (Ueda et al., 2001; Zheng and Chen, 2001; Balint et al., 2002; Fontemaggi et al., 2002; Sasaki et al., 2002) .
We found that the human ADA gene contains a putative p53 target site in intron 1. ADA is a crucial catabolic enzyme in the purine salvage pathway, which catalyses the irreversible deamination of adenosine and deoxyadenosine. The importance of ADA as a p53 family target gene lies in the fact that purine nucleotides and nucleosides are considered regulators of cell growth and differentiation, given the necessity to maintain a balance of deoxyinucleotides, to avoid severe genetic damage. Human syndromes due to a genetic deficiency of enzymes involved in DNA precursors metabolism prove the importance of such enzymes in the cell. Moreover, excessive amounts of some purine compounds cause cell death in developing thymocytes and in neural cells (Kizaki et al., 1988; Wakade et al., 1995) . Insufficient intracellular pools have been shown to be involved in the precocious differentiation of cultured intestinal cells (He et al., 1993) . Maintenance of these pools within acceptable limits is accomplished by enzymes of the purine and pyrimidine de novo and salvage pathways, such as the ADA enzyme. For these reasons the ubiquitous expression of the ADA gene is highly regulated and this regulation occurs via regulatory modules, which are responsible for the activation of ADA expression in a tissue-specific manner (Dusing et al., 1997) . In this study, we demonstrate that the ADA gene is a functional p73 target (Figures 2 and 5-7) . We found that p73 transactivates the ADA gene in response to the dNTP pools unbalance generated by ADA enzyme deficit (Figures 7 and 8) . Indeed, the ADA activity deficit produces the accumulation of its substrate dAdo, which cannot be converted into dIno and is phosphorylated in dATP. The abnormal accumulation of dATP leads to the inhibition of ribonucleotide reductase (RD) and an imbalance in dNTP levels because of the lower levels of the other three deoxynucleoside triphosphates. As a result of this unbalance, both DNA repair and replicative DNA synthesis are inhibited (Camici et al., 1995; Bemi et al., 1998) . We found for the first time that the ADA deficit and dAdo accumulation, caused by dCF plus dAdo, induces the arrest of the cells in the G1 and S phase with the activation of p73 and an increase in ADA mRNA expression in the p53-null H1299 cell line (Figure 7) . We suggest that p73 could promote the recovery of the cell by inducing ADA gene expression by a feedback regulation mechanism probably in cooperation with other defined regulatory factors, which regulate the basal expression of the gene (Dusing and Wiginton, 1994) (Figure 8 ). We cannot exclude that, as reported for p53, p73 could also induce apoptosis in some cellular contexts (Lissy et al., 2000) . Further study should be interesting to investigate whether p63 also can transactivate ADA gene expression.
The correlation between ADA and p73 is reinforced by the evidence that both genes are differentially expressed in tissues and are involved in development. Indeed, although the main function of ADA is the development of the immune systems in humans, it also seems to be associated with the differentiation of epithelial cells and monocytes, neurotransmission and maintenance of gestation (Moriwaki et al., 1999) ; besides, increasing evidences indicate that maintaining high levels of ADA in mice placenta is essential for embryonic and fetal development (Blackburn et al., 1995; Shi et al., 1997) . All these observations indicate that the ADA protein is critical for development and cell proliferation.
Moreover, our observation demonstrates that ADA does not appear to be a functional p53 target in the physiological conditions we tested (Figures 3 and 4) . Although CAT assays demonstrate that ADA-RE is regulated with high efficiency by p73b isoform, ADA-RE also showed enhancer activity for p53 (Figure 2a ). This result highlights the fact that the presence of a p53 binding sequence is necessary, but not sufficient to define a gene as a p53 target. Although several studies have tried to define the features of the p53 consensus better, they are still far from being satisfactorily described. Moreover, further studies will be needed to define whether the p73 preferential target genes have a responsive element with structural peculiar features, which differentiate them from those of p53 preferential target genes or whether p53 and p73 interact with different proteins to recruit different target genes selectively.
It is likely that sequence conformation may provide additional specificity over the primary sequence alone and that conformation based on chromatin structure may provide greater specificity for p53 target genes. Recently, it has been demonstrated that the specificity of the consensus is correlated with the propensity of DNA to bend (Nagaich et al., 1997; Zhou et al., 2001 ). The energy of DNA bending could contribute significantly to the site-specific binding of p53 and p73 isoforms with the REs.
As a whole, our studies contribute to mark a divergence in p53 family members roles, further distinguishing the function of p53 from p73 and p63. This also emerges from the evolutionary analysis of p53 family members, from which it appears that p53, p63 and p73 derive from a common ancestor by two duplication events (Saccone et al., 2002) . The first duplication generated p53 and the p63/p73 precursor. Later on, a second duplication event gave rise to p63 and p73. This evolutionary pattern and the high conservation between p63 and p73 suggest that in vertebrates, p63 and p73 genes have crucial functions for organism survival, distinct from those of p53. Figure 8 Schematic diagram of the dAdo metabolism. The enzymes involved in the metabolism of the ADA substrate, dAdo, can be placed into two categories: 'activating' enzymes with phosphorylating activity (black arrows), which could convert dAdo into the cytotoxic agents (dATP); 'inactivating' enzymes (white arrows), such as ADA, involved in the conversion of dAdo and/or its derivates into nontoxic compounds (dAdo, dIno). A deficit of ADA activity and the accumulation of its substrate (dAdo) affects two metabolic pathways. One metabolic consequence of the accumulation of dAdo is inactivation of the enzyme S-adenosylhomocysteine hydrolase (AHCY), resulting in the accumulation of its substrate with consequent inhibition of specific S-adenosylmethionine-dependent methylation of nucleic acids, proteins and lipids. The second pathway involves abnormal accumulation of dATP (the phosphorylated end product of the ADA substrate dAdo) that leads to inhibition of RD due to an unbalance in dNTP levels, because of the lower levels of the other three deoxynucleoside triphosphates. As a result of this unbalance, both DNA repair and replicative DNA synthesis are inhibited. It has been reported that this inhibition determines p53 activation and apoptosis. We demonstrate that the inhibition of DNA replication due to ADA enzyme deficit also activates p73 that could induce, probably together with Sp1, ADA gene expression by a feedback mechanism
Materials and methods

Cell culture
MCF-7, H1299, A2780 and SAOS-2 cell lines were cultured in Dulbecco's modified Eagle's medium (DMEM) plus 10% fetal calf serum (FCS), penicillin (100 U/ml) and streptomycin (100 mg/ml) at 371C, 5% CO 2 .
UV treatment consisted in a 10 J/m 2 performed in a CL-1000 Ultraviolet Crosslinker (UVP).
Transient cotransfection and CAT assays
An 367 bp fragment containing the p53-RE in the intron 1 of ADA gene (13813-14180-GenBank accession no. M13792) was amplified from the human genome DNA and cloned upstream the reporter CAT gene in the pBLCAT2 vector, which contains the herpes simplex virus tk promoter that permits the analysis of the effects of putative regulatory elements on a heterologous eucaryotic promoter. The resulting recombinant plasmid is defined as ADA-RE (Figure 1 ). The mutant fragment was created by a standard PCR-based site-directed mutagenesis procedure and defined mut-ADA-RE (Figure 1) .
A total of 2.5 Â 10 5 of human p53-null H1299 cells were cultured in 6 cm culture dishes 24 h before transfection (about 60-80% confluency). In all, 2.5 mg of pG13CAT or pBLCAT2 recombinant vectors containing ADA-RE or mut-ADA-RE plus 0.5 mg of an expression vector containing either wt p53 or the H175 mutant version or either p73a and p73 b splice variants or the V156A mutant p73, plus 0.1 mg of pSVb-gal (Stratagene) were incubated in 100 ml of serum-free medium and 8 ml of Fugene (Roche) for 15 min at room temperature and subsequently added to the cell cultures. Then the cells were cultured in DMEM plus serum for 48 h. The transfection efficacy was determined by b-galactosidase activity (b-gal assay, Roche). CAT expression was determined in duplicate using a CAT-ELISA (Roche) and calculated as ng CAT protein/mU b-gal. The data reported represent the average of at least three independent experiments and are shown with the standard deviations.
Western blot analysis
Cells were lysed with RIPA buffer (50 mm Tris-HCl pH 7.5, 150 mm NaCl, 1% Nonidet P40, 0.5% sodium deoxycholate, 0.1% SDS, protease inhibitors cocktail tablets (Roche)) for 1 h on ice. Then the lysates were clarified by centrifuged at 13 600 g at 41C, aliquoted and stored at À201C. In all, 50 or 300 mg (for p73 immunoreaction) of the total proteins in 2 Â SDS-PAGE sample buffer were heated at 951C for 2 min and submitted to 12.5 or 10% SDS-PAGE.
The separated proteins were electroblotted onto Nitrocellulose PROTRAN s BA85 (Schleicher and Schuell). Blots were exposed for 60 min at room temperature to the following primary antibodies: CM1 (anti-p53 polyclonal), p21/Waf1 (Ab-1, Calbiochem), p73 (monoclonal antibody to human p73 (IMGENEX). Bound primary antibodies were visualized using ECL Western blotting detection reagents (Amersham Pharmacia Biotech).
Northern blotting
Total RNA from different cell lines was extracted using the RNasy mini kit (Qiagen). For Northern blotting, 15-20 mg of total RNA for each lane was separated on 1.2% agarose gels containing 6.66% formaldehyde and transferred onto a nylon membrane (Hybond N þ , Amersham) . Hybridization was performed under high stringency conditions. The fragments corresponding to ADA exon 4, to G3PDH, to actin, Waf1/ p21, GADD45 or p57
Kip2 were labeled using a random priming procedure (Random Primed DNA Labeling kit, Roche) and used as a probe.
Chromatin immunoprecipitation assay
A2780 cells were cultured in 15-cm culture dishes 24 h before transfection (about 60-80% confluency). A total of 2 mg of pcDNA3-p73a or pcDNA3-p73b were incubated in 200 ml of serum-free medium plus 6 ml of Fugene (Roche) for 15 min at room temperature and subsequently added to the cell cultures. Then the cells were cultured in DMEM plus serum for 24 h. Proteins were crosslinked to DNA in living nuclei by adding formaldehyde directly to a cell culture medium to a final concentration of 1%. Crosslinking was allowed to proceed for 10 min at 371C. Crosslinked cells were washed with phosphatebuffered saline (PBS), scraped off the plates and resuspended in 20 mm Tris-chloride pH ¼ 8.3, 3 mm MgCl 2 , 20 mm KCl, 1 mm phenylmethylsulfonyl fluoride, 1 mg/ml leupeptin, 1 mg/ml aprotinin. Nuclei were pelleted by microcentrifugation and lysed by incubation in nuclear lysis buffer (1% sodium dodecyl sulphate, 10 mm EDTA, 50 mm Tris-chloride pH ¼ 8.1, 1 mm phenylmethylsulfonyl fluoride, 1 mg/ml leupeptin, 1 mg/ml aprotinin). The resulting chromatin solution was sonicated for 10 sets of 6 s pulses at 40 W to generate 300-2000 bp DNA fragments. After microcentrifugation, the supernatant was diluted 1 : 10 with a dilution buffer (0.01% sodium dodecyl sulfate, 1.1% Triton X-100, 1.2 mm EDTA, 16.7 mm Trischloride pH ¼ 8.1, 167 mm NaCl, 1mM phenylmethylsulfonyl fluoride, 1 mg/ml leupeptin, 1 mg/ml aprotinin) and precleared with protein A-agarose/salmon sperm DNA and divided into aliquots. In total, 5 mg of p73 antibodies (Ab p73-H79 and Ab p73-C20 Santa Cruz) or any antibody (as negative control) were added to the chromatin solution and incubated on a rotating platform for 12-16 h at 41C. Antibody-protein-DNA complexes were precipitated with protein A-agarose/salmon sperm DNA. After centrifugation, the beads were washed and the protein-DNA complexes were eluted with 1% sodium dodecyl sulfate, 100 mm sodium carbonate. DNA-protein crosslinks were reversed by heating at 651C for 4 h and DNA was phenol extracted and ethanol precipitated. DNA fragments were analysed by PCR using primers specific for the ADA-RE and interleukin-10 promoter, used as a negative control.
Tunel
Cells cultured on chamber slides were rinsed with PBS and fixed in PBS/4% paraformaldehyde solution for 1 h at room temperature, washed three times with PBS and incubated with a blocking solution (0.3% H 2 O 2 in methanol) for 1 h at room temperature. The slides were then rinsed with PBS and incubated in a permeabilization solution (0.1% Triton X-100 in 0.1% sodium citrate) for 2 min on ice. The slides were rinsed with PBS and incubated with TUNEL reaction mixture (Roche) in a humidified chamber for 1 h at 371C, washed three times with PBS covered with mounting medium (1% Npropyl gallate, 50% glycerol in 1 Â PBS) and analysed under a fluorescence microscope. As a positive control, MCF-7 and H1299 cells were treated for 10 min at room temperature with 1 mg/ml DNase I in 10 mm Tris-HCl pH ¼ 7.5, 1 mm MgCl 2 , 1 mg/ml BSA.
Flow-cytometric analysis
To induce an ADA deficit, we used dCF, a potent ADA inhibitor plus ADA substrate dAdo. The day before the dCF and dAdo treatment, 1-1.5 Â 10 6 cells were seeded into a 100 mm diameter Petri dish. The total population of treated cells, including floating and adherent cells, was harvested at the indicated times and fixed in 75% ethanol for at least 2 h at À201C. The cells were then rehydrated in cold PBS, pelleted and treated with 150 mg/ml RNase A for 30 min at 371C and stained with 5 mg/ml propidium iodide for 45 min The cells were analysed in a FACScalibur; cell cycle and apoptosis analyses were performed with ModFit analysis software (Becton Dickinson).
